A double-blind, randomised, placebo-controlled, comparative induced pain model to investigate topical diclofenac (TPR 100), topical ibuprofen (TIB 200) and topical methyl salicylate (SPR 300) in healthy volunteers

Trial Profile

A double-blind, randomised, placebo-controlled, comparative induced pain model to investigate topical diclofenac (TPR 100), topical ibuprofen (TIB 200) and topical methyl salicylate (SPR 300) in healthy volunteers

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Jul 2016

At a glance

  • Drugs Diclofenac (Primary) ; Ibuprofen (Primary) ; Methyl salicylate (Primary)
  • Indications Pain
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 14 Jul 2015 Primary endpoint has not been met. (Primary pain management (heat pain tolerance test) of SPR300), according to a Futura Medical media release.
    • 14 Jul 2015 Primary endpoint has been met. (Primary pain management (heat pain tolerance test) of TIB200), according to a Futura Medical media release.
    • 14 Jul 2015 Primary endpoint has been met. (Primary pain management (heat pain tolerance test) of TPR100), according to a Futura Medical media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top